|CRIADO, MIRIA - Auburn University|
|KASSA, AEMRO - Boehringer Ingelheim|
|BERTRAN, KATERI - Consultant|
|KWON, JUNG-HOON - Kyungpook National University|
|SA E SILVA, MARIANA - Boehringer Ingelheim|
|ROSS, TED - University Of Georgia|
|MEBATSION, TESHOME - Boehringer Ingelheim|
Submitted to: Vaccine
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: 3/24/2023
Publication Date: 5/2/2023
Citation: Criado, M.F., Kassa, A., Bertran, K., Kwon, J., Sa E Silva, M., Killmaster, L.F., Ross, T.M., Mebatsion, T., Swayne, D.E. 2023. Efficacy of multivalent recombinant herpesvirus of turkey vaccines against high pathogenicity avian influenza, infectious bursal disease, and Newcastle disease viruses. Vaccine. 41(18):2893-2904. https://doi.org/10.1016/j.vaccine.2023.03.055.
Interpretive Summary: Vaccines are an essential tool for the control of viral infections in poultry. We combined vaccine antigens from H5 high pathogenicity avian influenza (HPAI), infectious bursal disease (IBD) and Newcastle disease (ND) in an advanced biotechnology vaccine virus, herpesvirus of turkey (vHVT), to produce two multivalent vaccines vHVT-IBD-AI and vHVT-ND-AI. These new vaccines protected chickens against H5 HPAI, IBD and ND. Our findings demonstrate that multivalent vHVT vector vaccines are efficacious for simultaneous control of HPAI and other viral infections for which routine vaccination is implemented.
Technical Abstract: Vaccines are an essential tool for the control of viral infections in domestic animals. We generated recombinant vector herpesvirus of turkeys (vHVT) vaccines expressing computationally optimized broadly reactive antigen (COBRA) H5 of avian influenza virus (AIV) alone (vHVT-AI) or in combination with virus protein 2 (VP2) of infectious bursal disease virus (IBDV) (vHVT-IBD-AI) or fusion (F) protein of Newcastle disease virus (NDV) (vHVT-ND-AI). In vaccinated chickens, all three vHVT vaccines provided 90-100% clinical protection against three divergent clades of high pathogenicity avian influenza viruses (HPAIVs), and significantly decreased number of birds and oral viral shedding titers at 2 days post-challenge compared to shams. Four weeks after vaccination, most vaccinated birds had H5 hemagglutination inhibition antibody titers, which significantly increased post-challenge. The vHVT-IBD-AI and vHVT-ND-AI vaccines provided 100% clinical protection against IBDVs and NDV, respectively. Our findings demonstrate that multivalent HVT vector vaccines were efficacious for simultaneous control of HPAIV and other viral infections.